What is Opdivo (nivolumab) and what cancers does it treat?
Opdivo is a cancer medicine made from nivolumab, an immune checkpoint inhibitor that helps the immune system recognize and attack cancer cells. It is used in multiple cancer types, including lung cancer, melanoma, kidney cancer, bladder cancer, head and neck cancer, Hodgkin lymphoma, stomach/GE junction cancer, and other solid tumors, depending on the specific indication and treatment setting [1][2].
How does Opdivo work?
Opdivo blocks PD-1 (programmed death-1) on T cells. By inhibiting this checkpoint, it can restore or enhance T-cell activity against tumor cells [1].
How is Opdivo given (infusion, schedule)?
Opdivo is administered as an intravenous (IV) infusion. The exact dose and frequency can vary by cancer type and treatment regimen, based on the approved prescribing information and the oncology treatment plan [1].
What side effects do patients ask about most?
Common side effects can include fatigue and immune-related problems (because it changes immune activity). Immune-related adverse events can affect organs such as the skin, intestines, liver, lungs, and endocrine glands. Serious immune reactions can occur and may require prompt treatment and, in some cases, stopping Opdivo [1][2].
What immune-related adverse events should be watched for?
Typical immune-related toxicities can include inflammation of the colon (colitis/diarrhea), lungs (pneumonitis), liver (hepatitis), and endocrine organs (hormone gland inflammation). If symptoms suggest an immune reaction, clinicians usually evaluate quickly and may use corticosteroids and other immune-suppressing treatments [1][2].
What cancers are commonly treated with Opdivo in combination therapies?
Opdivo is sometimes used with other anticancer drugs or immunotherapies, such as chemotherapy combinations or other immune checkpoint agents, depending on the tumor type and stage. The best-known combinations vary by indication and guideline practice, and the regimen is chosen based on evidence for that specific cancer [1][2].
Who makes Opdivo and where does it fit vs. Keytruda or other PD-1 drugs?
Opdivo is nivolumab. Another widely used PD-1 inhibitor is pembrolizumab (Keytruda). Which one is used depends on the exact cancer type, prior treatment history, biomarker status (when required), and evidence from clinical trials for that indication [1][2]. Direct head-to-head comparisons are not uniform across cancers, so oncologists choose based on label-indication data and patient-specific factors.
Is Opdivo available as generics or biosimilars?
As with many biologic cancer medicines, availability of lower-cost alternatives depends on whether and when biosimilars are approved and launched in a given country. For current availability, it’s important to check the local formulary and the latest regulatory updates for nivolumab products [2].
What should patients know before starting?
Patients are generally assessed for baseline autoimmune conditions and for symptoms that could signal organ issues. During treatment, they are monitored for side effects and for changes in lab tests that can indicate inflammation. Patients are advised to report new or worsening symptoms quickly so immune-related toxicity can be managed early [1][2].
---
Sources
[1] https://www.opdivo.com/
[2] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm